Streptococcus pneumonia remains one of the most commonly identified pathogen associated with hospitalization and death among children and adults (1) .
Despite improvements in diagnostic tests and treatment regimens, mortality remains high ranging from 5 to 35% (1).
Worldwide, an estimated 541,000 deaths were attributed to pneumococcal disease in children <5 years in 2008 and nearly all of them occurred in low-income countries. Among the wealthy population, nearly all deaths due to pneumococcal disease occur in the elderly, as children in these populations are routinely vaccinated against pneumococcal disease using pneumococcal conjugate vaccines (PCVs) (1,2).
Pneumococcus has different serotypes that differ based on their antigenically distinct polysaccharide capsules.
These serotypes have variable virulence. Some of them are associated with increased degree of disease severity, increased risk of invasiveness (meningitis and bacteremia), increased fatality rate and exhibit antibiotic resistance (3, 4) .
Pneumococcal disease is largely preventable. Two main types of vaccines are available, and approved for use in adults:
1) Polysaccharide 23-valent pneumococcal vaccine.
2) 13-valent PCVs.
The routine use of 13-valent PCV in children has markedly reduced pneumococcal disease not only in children, but also in adults by the way of indirect protection also known as herd effect (2, 5) .
In adults, the incidence of meningitis and bacteremia Twelve of the 13 serotypes in PCV 13 are in PPS V23.
PPSV23 can protect against invasive pneumococcal disease but its effectiveness against cap has not been well proven.
Unlike PCV13, PPSV23 is not approved for children less than 2 years of age (9, 10).
Candidates of vaccine:
While any one can develop pneumococcal disease, it most often affects susceptible individuals such as infants, the elderly and people of any age with underlying medical conditions causing immunodeficiency.
For example, patients with AIDS have disease rates up to 100 times than those seen in healthy persons (11, 12) . Optimal interval between dose of PCV13 and PPSV23 has been shown in Table 1 (adopted from reference 10). Abbreviation: NA= Not applicable, sequential use of PCV13 and PPSV23 is not recommended for these and risk group.
*Underlying medical conditions that are not included in the recommendations for children aged <2 years.
